期刊
BLOOD
卷 109, 期 5, 页码 2165-2173出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2006-06-028092
关键词
-
类别
资金
- NCI NIH HHS [R01 CA098110, R01 CA096500, CA096500, R01 CA163217, R01 CA109232, CA112935, CA109232, CA098110] Funding Source: Medline
- NHLBI NIH HHS [HL083469, R01 HL083469] Funding Source: Medline
- NIAID NIH HHS [AI057157, U54 AI057157] Funding Source: Medline
- NIDCR NIH HHS [R01 DE018304-01, R01 DE018304-03, R01 DE018304-02, R01 DE018304] Funding Source: Medline
The antitumor potency of the mTOR inhibitor rapamycin (sirolimus) is the subject of intense investigations. Primary effusion lymphoma (PEL) appears as an AIDS-defining lymphoma and like Kaposi sarcoma has been linked to Kaposi sarcoma-associated herpesvirus (KSHV). We find that (1) rapamycin is efficacious against PEL in culture and in a murine xenograft model; (2) mTOR, its activator Aid, and its target p70S6 kinase are phosphorylated in PEL; (3) rapamycin inhibits mTOR signaling as determined by S6 phosphorylation; (4) KSHV transcription is unaffected; (5) inhibition of IL-10 signaling correlates with drug sensitivity; and (6) addition of exogenous IL-10 or IL-6 can reverse the rapamycin growth arrest. This validates sirolimus as a new treatment option for PEL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据